Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid hormone: evolving therapeutic concepts.

Nancy E Lane1

  • 1University of California at San Francisco, CA 94143, USA. nelane@itsa.ucsf.edu

Current Opinion in Rheumatology
|June 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning-based quantification of knee effusion-synovitis volume on MRI - Technique development and validation.

Osteoarthritis and cartilage·2026
Same author

Elevated Serum CXCL9 Levels Are Associated with Greater Frailty Risk in Older Women.

Endocrinology and metabolism (Seoul, Korea)·2026
Same author

Association between central obesity and MRI-based biomarkers of knee osteoarthritis independent of BMI: A cross-sectional study from the Osteoarthritis Initiative database.

Osteoarthritis and cartilage open·2026
Same author

Sex- and site-specific associations between hemoglobin levels and cortical bone structure and microarchitecture in older adults.

Bone·2026
Same author

Transcriptomic Profiling in Skeletal Muscle Identifies Associations With Knee Osteoarthritis: the Study of Muscle, Mobility and Aging (SOMMA).

medRxiv : the preprint server for health sciences·2026
Same author

Greater recalled pain and movement-evoked pain are associated with longer 400-m walk and repeat stair climb timein older adults: the study of muscle, mobility, and aging.

GeroScience·2026
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Parathyroid hormone (recombinant human parathyroid hormone 1-34) is a novel osteoanabolic agent for osteoporosis treatment. Initial studies show its effectiveness in improving bone strength and reducing bone loss.

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Osteoporosis is characterized by reduced bone mass and structural integrity, increasing fracture risk.
  • Antiresorptive agents are commonly used to manage bone loss.
  • Recombinant human parathyroid hormone 1-34 represents a new class of osteoanabolic agents.

Purpose of the Study:

  • To review Phase 2 and Phase 3 clinical studies on the efficacy of parathyroid hormone (recombinant human parathyroid hormone 1-34) for osteoporosis.
  • To evaluate the use of parathyroid hormone in combination with antiresorptive therapies.
  • To discuss current knowledge gaps regarding the optimal duration of parathyroid hormone treatment.

Main Methods:

  • Systematic review of published Phase 2 and Phase 3 clinical trials.

Related Experiment Videos

  • Analysis of studies investigating parathyroid hormone as monotherapy and in combination with antiresorptive agents.
  • Discussion of safety and efficacy data from clinical studies.

    • Main Results:

    • Parathyroid hormone (recombinant human parathyroid hormone 1-34) stimulates bone formation on all bone surfaces.
    • Clinical studies demonstrate the effectiveness of this agent in treating osteoporosis.
    • Combination and sequential use with antiresorptive agents are under investigation.

    Conclusions:

    • Parathyroid hormone compounds are a significant advancement in osteoporosis management.
    • Further research is needed to optimize the clinical application and duration of parathyroid hormone therapy.
    • Continued investigation will refine the use of these agents for improved patient outcomes.